IL1R1:IL1RAP binds IL1R1 inhibitors

Stable Identifier
R-HSA-9681763
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The IL1 family includes two agonists, IL1α and IL1β, and a naturally occurring receptor antagonist, IL1Ra. IL1Ra is produced locally in various tissues in response to infection or inflammation (Arend & Gabay 2000). Anakinra (Kineret) is a recombinant form of IL1Ra that competitively inhibit the local inflammatory effects of IL1 and is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate (Drevlow et al. 1996, Cohen et al. 2002, Fleischmann et al. 2003). Isunakinra (EBI 005) is a fusion protein containing domains from IL1β and the IL1 receptor antagonist (IL1Ra or anakinra) developed as a topical therapy for dry eye disease (Goldstein et al. 2017). It blocks IL1R1 signalling with higher affinity than anakinra (Kovalchin et al. 2018). These IL1R1 inhibitors may be investigated for their role in blocking inflammatory cytokines produced in the "cytokine storm syndrome" caused by COVID-19 (Cron & Chatham 2020).

Literature References
PubMed ID Title Journal Year
11094434 Physiologic role of interleukin-1 receptor antagonist

Arend, WP, Gabay, C

Arthritis Res. 2000
27466718 Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease

Goldstein, MH, Martel, JR, Sall, K, Goldberg, DF, Abrams, M, Rubin, J, Sheppard, J, Tauber, J, Korenfeld, M, Agahigian, J, Durham, TA, Furfine, E

Eye Contact Lens 2017
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!